New Approacher in the Development of Alzheimer’s Disease Modifying Drugs

Pedro César de Souza1*, Emmilli Emmanuelle Souza Lins Lima de Carvalho1, Patrícia Maria da Silva Neri Cruz2

1 University Center Mauricio de Nassau, Recife, PE, Brasil; 2Federal University of Pernambuco, Recife, PE, Brasil.

Introduction: Alzheimer’s disease is a more common neurodegenerative disease, affecting 25 million people worldwide, or accounting for about 60 to 70% of all dementia cases. There is currently no exact mechanism to explain the pathophysiology of Alzheimer’s disease, however, cascading metabolic amyloid and post-translational review of tau protein are used as major hypotheses.

Objective: To demonstrate in the literature new approaches in the development of Alzheimer’s disease modifiers.

Methodology: For the accomplishment of this study made in the bibliographical survey of scientific literature and respect to the approached subject, in the databases PUBMED, ScienceDirect, Scielo and Scopus.

Results: Alzheimer’s disease-modifying drugs are not yet available, but many patients may, however, develop phase III clinical trials and are intended to modify as pathological stages leading to the disease. As disease-modifying therapies under study, these changes also affect Aβ and tau protein and also cause inflammation and oxidative damage. The results obtained in the clinical trials performed were positive and promising and are still under study. The results show that there is still a long way to go in the development of Alzheimer’s disease modifying drugs.

Conclusion: The results demonstrated that there is still a long way to go in the development of Alzheimer’s disease modifying drugs, but nevertheless levels at the research level should be continued in order to improve the pathophysiology of the disease and find an effective treatment for this disease the same.

Keywords: Alzheimer’s disease, β-amyloid, Tau hyperphosphorylation, Neurodegeneration

Free Full-text PDF

How to cite this article:
Pedro César de Souza, Emmilli Emmanuelle Souza Lins Lima de Carvalho, Patrícia Maria da Silva Neri Cruz. NEW APPROACHER IN THE DEVELOPMENT OF ALZHEIMER’S DISEASE MODIFYING DRUGS. International Journal of Aging Research, 2021, 4:88. DOI: 10.28933/ijoar-2021-07-2005


1. EU Joint Programme – Neurodegenerative Disease. What is neurodegenerative disease?. JPND. 2015
2. Taipa R, Pinho J, Melo-Pires M. Clinico-pathological correlations of the most common neurodegenerative dementias. Front Neurol. 2017 Jan;3:68.
3. Dalvi A. Alzheimer’s Disease. Dis Mon. 2018 Dec;58(12):666–77.
4. Castellani RJ, Rolston RK, Smith MA. Alzheimer Disease. Dis Mon. 2016 Sep;56(9):484–546.
5. Xiaoting S, Jin L, Ling P. Review of drugs for Alzheimer’s disease. Drug Discov Ther. 2017;6(6):285–90.
6. Mu Y, Gage FH. Adult hippocampal neurogenesis and its role in Alzheimer’s disease. Mol Neurodegener. 2016 Jan;6:85.
7. Dong S, Duan Y, Hu Y, Zhao Z. Advances in the pathogenesis of Alzheimer’s disease: a re-evaluation of amyloid cascade hypothesis. Transl Neurodegener. BioMed Central Ltd; 2018 Jan 21;1(1):18.
8. Galimberti D, Scarpini E. Disease-modifying treatments for Alzheimer’s disease. Ther Adv Neurol Disord. 2018;4(4):203–16.
9. Chu LW. Alzheimer’s disease: early diagnosis and treatment. Hong Kong Med J. 2018;18(3):228–37.
10. Alzheimer’s Disease International. Relatório sobre a Doença de Alzheimer no Mundo. 2018.
11. Sosa-Ortiz AL, Acosta-Castillo I, Prince MJ. Epidemiology of Dementias and Alzheimer’s Disease. Arch Med Res. Elsevier Inc; 2017;43(8):600–8.
12. Chen JH, Lin KP, Chen YC. Risk Factors for Dementia. J Formos Med Assoc. Formosan Medical Association & Elsevier; 2017;108(10):754–64.
13. World Health Organization. Dementia: a public health priority. World Health Organization. Reino Unido; 2017. Novas abordagens no desenvolvimento de fármacos modificadores da Doença de Alzheimer 64
14. Associação Alzheimer Portugal. Plano Nacional de Intervenção Alzheimer. 2016.
15. Fiţa IG, Enciu A-M, Stănoiu BP. New insights on Alzheimer’s disease diagnostic. Rom J Morphol Embryol. 2016 Jan;52(3 Suppl):975–9.
16. Anderson SH. Alzheimer Disease [Em linha]. Medscape. 2015 [Consult. 2015 Mar 23]. Disponível na Internet: overview
17. Morris JK, Honea RA, Vidoni ED, Swerdlow RH, Burns JM. Is Alzheimer’s disease a systemic disease? Biochim Biophys Acta. 2015 Sep;1842(9):1340–9.
18. Lemere CA. Immunotherapy for Alzheimer’s disease: hoops and hurdles. Mol Neurodegener. Molecular Neurodegeneration; 2016;8(1):36.
19. Perl DP. Neuropathology of Alzheimer’s Disease. Mt Sinai J Med. 2016;77(1):32– 42.
20. Serrano-Pozo A, Frosch MP, Masliah E, Hyman BT. Neuropathological Alterations in Alzheimer Disease. Cold Spring Harb Perspect Med. 2018;1(1):1– 24.

Terms of Use/Privacy Policy/ Disclaimer/ Other Policies:
You agree that by using our site, you have read, understood, and agreed to be bound by all of our terms of use/privacy policy/ disclaimer/ other policies (click here for details).

This work and its PDF file(s) are licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.